[1] TAN D J H,NG C H,LIN S Y,et al.Clinical characteristics,surveillance,treatment allocation,and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma:A systematic review and meta-analysis[J].Lancet Oncol,2022,23(4):521-530. [2] HABER P K,PUIGVEHÍ M,CASTET F,et al.Evidence-based management of hepatocellular carcinoma:Systematic review and meta-analysis of randomized controlled trials(2002-2020)[J].Gastroenterology,2021,161(3):879-898. [3] HARDING-THEOBALD E,LOUISSAINT J,MARAJ B,et al.Systematic review:Radiomics for the diagnosis and prognosis of hepatocellular carcinoma[J].Aliment Pharmacol Ther,2021,54(7):890-901. [4] LV T R,HU H J,REGMI P,et al.Sarcomatoid hepatocellular carcinoma versus conventional hepatocellular carcinoma:A systematic review and meta-analysis[J].J Cancer Res Clin Oncol,2022,148(7):1685-1696. [5] 祝恒琴,江帆.探讨个性化护理结合疼痛干预对肝癌介入术后患者疼痛程度及并发症的影响[J].现代消化及介入诊疗,2019,24(A02):2389-2389. [6] 祁慧,尹国文,徐清宇,等.原发性肝癌患者经动脉化疗栓塞术后化疗相关性恶心呕吐风险评估工具的编制及预测效能检验[J].中国实用护理杂志,2024,40(8):596-603. [7] 中华人民共和国国家卫生健康委员会.原发性肝癌诊疗指南(2022年版)[J].传染病信息,2022,35(1):1-26. [8] HUANG D Q,TAN D J H,NG C H,et al.Hepatocellular carcinoma incidence in alcohol-associated cirrhosis:Systematic review and meta-analysis[J].Clin Gastroenterol Hepatol,2023,21(5):1169-1177. [9] ORCI L A,SANDUZZI-ZAMPARELLI M,CABALLOL B,et al.Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease:A systematic review,meta-analysis,and meta-regression[J].Clin Gastroenterol Hepatol,2022,20(2):283-292.e10. [10] BAE S H,CHUN S J,CHUNG J H,et al.Stereotactic body radiation therapy for hepatocellular carcinoma:Meta-analysis and international stereotactic radiosurgery society practice guidelines[J].Int J Radiat Oncol Biol Phys,2024,118(2):337-351. [11] 张淑红,霍传红.消融治疗术后肝癌患者的相关生存质量研究[J].国际医药卫生导报,2019,25(6):846-848. [12] COLLETTI G,CINISELLI C M,SORRENTINO L,et al.Multimodal treatment of rectal cancer with resectable synchronous liver metastases:A systematic review[J].Dig Liver Dis,2023,55(12):1602-1610. [13] 陈胜灯. 碱性磷酸酶与前白蛋白比值对肝癌患者根治性切除术后预后及并发症的预测价值[D].泸州:西南医科大学,2023. [14] 张筱童,戴琪,戚志惠,等.肺癌患者术后恶心呕吐的危险因素及预测模型研究[J].现代医学,2022,50(12):1545-1549. [15] 尹哲,李媛,张静,等.胃癌术后患者化疗致恶心呕吐程度及其影响因素分析[J].新疆医科大学学报,2022,45(5):505-510. [16] 袁芮芮,刘海净,吴叶红,等.基于真实世界骨科术后康复影响因素及围术期用药分析[J].药物评价研究,2022,45(6):1127-1133. [17] 王若菡,李冰,袁景丽,等.胸科手术病人术后恶心呕吐的危险因素[J].中华麻醉学杂志,2022,42(2):143-146. [18] 杜瑞妮,杨岚,宋珂珂,等.术前焦虑对腹腔镜非胃肠手术患者术后恶心呕吐的影响[J].重庆医学,2023,52(8):1137-1140,1146. [19] GRANIERI S,ALTOMARE M,BRUNO F,et al.Surgical treatment of gastric cancer liver metastases:Systematic review and meta-analysis of long-term outcomes and prognostic factors[J].Crit Rev Oncol Hematol,2021(163):103313. [20] LEBECK LEE C M,ZIOGAS I A,AGARWAL R,et al.A contemporary systematic review on liver transplantation for unresectable liver metastases of colorectal cancer[J].Cancer,2022,128(12):2243-2257. [21] 梁轶,严忠婷,桑玉还,等.肝癌患者肝动脉化疗栓塞术后恶心和呕吐的危险因素及评估工具研究进展[J].介入放射学杂志,2024,33(5):565-570. [22] CALPIN G G,DAVEY M G,CALPIN P,et al.The impact of liver resection on survival for patients with metastatic breast cancer:A systematic review and meta-analysis[J].Surgeon,2023,21(4):242-249. [23] MILANO A F.Cancer of the liver,intrahepatic bile ducts,gallbladder,exocrine and neuroendocrine pancreas:20-year comparative survival and mortality analysis by age,sex,race,stage,grade,cohort entry time-period,disease duration & selected icd-o-3 oncologic phenotypes a systematic review of 367,420 cases for diagnosis years 1973-2014:(SEER*Stat 8.3.4)[J].J Insur Med,2022,49(2):60-96. [24] 周杉杉,丁红梅,徐雪萍,等.两种工具在原发性肝癌患者经动脉化疗栓塞术后延迟性化疗相关恶心呕吐风险评估中的比较[J].中华现代护理杂志,2022,28(4):452-457. [25] 白璐璐,牛瑛,王娇.饮食干预联合腹部热敷对肝癌TACE患者术后恶心、呕吐的影响[J].保健医学研究与实践,2022,19(12):127-130. [26] 张龙,王海溥,沈裕厚,等.高压氧辅助治疗对改善原发性肝癌患者TACE后不良反应及生活质量的作用观察[J].中华航海医学与高气压医学杂志,2023,30(6):750-754. |